LONDON (Alliance News) - Brain health company IXICO PLC Thursday said it has won contracts for two separate clinical trials in Huntington's disease with "top 15" pharmaceutical companies, building on a third clinical study already underway on the disease.
In a statement, IXICO said the two new clinical trials are starting imminently and are expected to last at least two years. IXICO will work with expert imaging centres across North America and Europe, with its technology to be used for handling and analysing imaging data.
Huntington's disease is a rare genetic neurodegenerative disorder that affects movement, cognition and behaviour.
"We are pleased to see our earlier research work in this area developing into an important commercial focus for IXICO. We look forward to supporting our pharmaceutical, clinical and academic colleagues in their efforts to find therapies for this very challenging condition," Chief Executive Derek Hill said in a statement.
"As new therapies are developed for neurodegenerative diseases such as Huntington's disease, technologies to diagnose these conditions in a timely way will become increasingly important and IXICO continues to invest in translating tools from the clinical trial market into our Assessa medical devices to support diagnosis," Hill added.
IXICO shares were Thursday quoted at 63.00 pence, up 5.0%.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2014 Alliance News Limited. All Rights Reserved.
Ixico (IXI)